Brexucabtagene autoleucel (original) (raw)
Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). The most common side effects include serious infections, low blood cell counts and a weakened immune system. The most common side effects for the treatment of ALL include fever, CRS, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting.
| Property | Value |
|---|---|
| dbo:abstract | Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). The most common side effects include serious infections, low blood cell counts and a weakened immune system. The most common side effects for the treatment of ALL include fever, CRS, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting. Brexucabtagene autoleucel is a chimeric antigen receptor T cell therapy and is the first cell-based gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma. Brexucabtagene autoleucel was approved for medical use in the United States in July 2020, and in the European Union in December 2020. (en) |
| dbo:alternativeName | Tecartus (en) |
| dbo:drugbank | DB15699 |
| dbo:fdaUniiCode | 4MD2J2T8SJ |
| dbo:kegg | D11880 |
| dbo:wikiPageID | 64640677 (xsd:integer) |
| dbo:wikiPageLength | 12975 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1122713393 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Priority_review dbr:Non-Hodgkin's_lymphoma dbr:Cytokine_release_syndrome dbr:Intravenous_therapy dbr:Gene_therapy dbr:Orphan_drug dbr:Boxed_warning dbr:Axicabtagene_ciloleucel dbc:Gilead_Sciences dbr:Acute_lymphoblastic_leukemia dbc:Orphan_drugs dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Risk_Evaluation_and_Mitigation_Strategies dbc:Gene_therapy dbc:Breakthrough_therapy dbc:Cancer_treatments dbr:Accelerated_approval_(FDA) dbr:Chimeric_antigen_receptor_T_cell dbr:Mantle_cell_lymphoma dbr:T_cell dbr:B-cell |
| dbp:atcPrefix | None (en) |
| dbp:dailymedid | Brexucabtagene_autoleucel (en) |
| dbp:drugbank | DB15699 (en) |
| dbp:kegg | D11880 (en) |
| dbp:legalCa | Rx-only (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:licenceUs | Tecartus (en) |
| dbp:pregnancyAu | C (en) |
| dbp:pregnancyCategory | Not recommended (en) |
| dbp:routesOfAdministration | dbr:Intravenous_therapy |
| dbp:synonyms | KTE-X19 (en) |
| dbp:tradename | Tecartus (en) |
| dbp:unii | 4 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Cite_journal dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates dbt:Drugs.com dbt:ClinicalTrialsGov |
| dct:subject | dbc:Gilead_Sciences dbc:Orphan_drugs dbc:Gene_therapy dbc:Breakthrough_therapy dbc:Cancer_treatments |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL). The most common side effects include serious infections, low blood cell counts and a weakened immune system. The most common side effects for the treatment of ALL include fever, CRS, hypotension, encephalopathy, tachycardias, nausea, chills, headache, fatigue, febrile neutropenia, diarrhea, musculoskeletal pain, hypoxia, rash, edema, tremor, infection with pathogen unspecified, constipation, decreased appetite, and vomiting. (en) |
| rdfs:label | Brexucabtagene autoleucel (en) |
| owl:sameAs | wikidata:Brexucabtagene autoleucel https://global.dbpedia.org/id/D4QY1 |
| prov:wasDerivedFrom | wikipedia-en:Brexucabtagene_autoleucel?oldid=1122713393&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Brexucabtagene_autoleucel |
| is dbo:wikiPageRedirects of | dbr:Tecartus |
| is dbo:wikiPageWikiLink of | dbr:List_of_gene_therapies dbr:Intracellular_delivery dbr:Gene_therapy dbr:Lymphoma dbr:Acute_lymphoblastic_leukemia dbr:Mantle_cell_lymphoma dbr:CAR_T_cell dbr:Tecartus |
| is foaf:primaryTopic of | wikipedia-en:Brexucabtagene_autoleucel |